Analysts flagged concerns over achieving oncology revenue targets amid dependency on ENHERTU’s growth to offset Datroway’s shortfall. Daiichi Sankyo’s Q3 FY2024 results reflect strong ...

A US jury has decided that Daiichi Sankyo and AstraZeneca's breast cancer drug Enhertu infringes a patent held by US biotech Seagen, awarding almost $42 million in damages. Seagen claims Enhertu ( ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval for their ... the partners have secured a seventh nod for their original ADC, Enhertu. The U.S. regulator has cleared Enhertu ...

Following this approval for Enhertu in the U.S., AstraZeneca is due $175 million as a milestone payment to Daiichi Sankyo. Daiichi Sankyo recognizes Enhertu sales in the U.S. AstraZeneca reports ...

(AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive ...

Narrow-moat Daiichi Sankyo’s third-quarter earnings were ... However, it depends on the continued momentum of Enhertu, which remains strong so far. We expect multiple key data readouts this ...

AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has approved the supplemental biologics license application (sBLA) seeking approval for expanded use of Enhertu (trastuzumab ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from the US Food and Drug Administration (FDA) for an expanded indication of ...

2024 AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels ...